Evaluation of Salmeterol or Montelukast as Second-Line Therapy for Asthma Not Controlled With Inhaled Corticosteroids
- 1 April 2001
- Vol. 119 (4), 1021-1026
- https://doi.org/10.1378/chest.119.4.1021
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patientsBMJ, 1999
- Fortnightly review: Modern drug treatment of chronic asthmaBMJ, 1999
- Leukotriene-receptor antagonistsThe Lancet, 1999
- Subsensitivity to bronchoprotection against adenosine monophosphate challenge following regular once-daily formoterolEuropean Respiratory Journal, 1998
- Potential Masking Effects of Salmeterol on Airway Inflammation in AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Effects of Treatment with Formoterol on Bronchoprotection against MethacholineThe American Journal of Medicine, 1998
- Effect of Inhaled Formoterol and Budesonide on Exacerbations of AsthmaNew England Journal of Medicine, 1997
- Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group.American Journal of Respiratory and Critical Care Medicine, 1997
- Inhaled Corticosteroids Do Not Prevent the Development of Tolerance to the Bronchoprotective Effect of SalmeterolChest, 1996
- Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patientsThe Lancet, 1995